Kent Lake Capital’s ADMA Biologics ADMA Stock Holding History

Kent Lake Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-271,119	Closed	-$537K	–	38
2022 Q2	$537K	Buy	+271,119	New	+$533K	0.3%	43

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Kent Lake Capital's ADMA Position: Q3 2022 in Review

Kent Lake Capital sold out of ADMA Biologics (ADMA) in Q3 2022, closing a stake of 271,119 shares — an estimated $537K sold.

Kent Lake Capital first reported a position in ADMA in Q2 2022 and held it in 1 quarter. The position peaked at $537K in Q2 2022. 130 funds tracked by Wall St. Rank hold ADMA as of Q3 2022.

Kent Lake Capital reported no remaining ADMA Biologics position as of Q3 2022 after selling out during the quarter.
Kent Lake Capital sold 271,119 ADMA Biologics shares in Q3 2022, an estimated $537K.
Kent Lake Capital first reported a position in ADMA Biologics in Q2 2022 and held it in 1 quarter.
Kent Lake Capital's ADMA Biologics position peaked at $537K in Q2 2022.
130 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2022.

Based on Kent Lake Capital's 13F filing for Q3 2022, filed 14 Nov 2022.